Description
Created On: 2020-07-15
Record Count: 8
Primary Industries
- Drugs
- Vaccine
- Cancer
- Disease
- Therapeutic
- DNA
- HIV / AIDs
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 230762
This agreement also includes a non-exclusive and exclusive grant back from Licensee to Licensor.
L523S Vaccine shall mean a Vaccine which contains all or a portion of the L523S Antigen.
Licensor Patents shall mean all patents and patent applications; that cover patentable inventions or discoveries made by Licensor solely or together with a Third Party in the course of the Initial Agreement Activities, or, that cover patentable inventions or discoveries that generically or specifically claim all or any part of any L523S, Vaccine, a process for manufacturing any L523S: Vaccine, intermediates used in such process or a use of any L523S Vaccine, and which are now or become owned and/or controlled by Licensor and/or under which Licensor otherwise has, now or in the future, the right to grant licenses. Included within the definition of Licensor Patents are any continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, improvement patents and/or foreign counterparts thereof. In no event shall Licensor Patents be deemed to include the Licensee Patents.
Licensee Products shall mean all Licensee Antibody Products and Licensee Vaccine Product.
L523S is an RNA-binding protein as a potential therapeutic target for lung cancer.
IPSCIO Record ID: 232446
This agreement also includes a non-exclusive grant back from Licensee to Licensor.
Licensor Adjuvant Know-How shall mean any technical information, materials or know-how exclusively related to any adjuvant owned or controlled by Licensor, including without limitation the protein Leishmania Elongation Initiation Factor, known as LeIF, MPL, or any synthetic adjuvant.
Antigen(s) shall mean the antigens and/or protein and/or other physical form based on such antigens, such as peptides and/or nucleic acids(s) (DNA, RNA) delivered in any form, including recombinant vectors, to the extent such antigens are covered by one or more Valid Claim(s) of any of the Licensor Patents.
IPSCIO Record ID: 249713
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.
In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens:
• Any and all Antigens expressed in Lung Cancer
The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.
Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.
IPSCIO Record ID: 257492
With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.
As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.
Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases: provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.
Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.
Treatment vaccines means a bulk or finished vaccine.
IPSCIO Record ID: 280951
BLP25 is a cancer vaccine being developed by Licensee containing a synthetic 25 amino acid sequence of the MUC-1 cancer mucin encapsulated in a liposomal delivery system and designed to induce an immune response to cancer cells.
IPSCIO Record ID: 248395
Licensed Product shall mean a Plague Antigen, and/or a Vaccine including but not limited to a Plague Vaccine Dose, the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.
Plague Antigen shall mean individually each of the F1 antigen and V antigen of Yesinnia Pestis.
Plague Vaccine Dose shall mean the quantity of Vaccine given to an individual in a single dose.
Patents are for Plague Vaccines and Vaccine Compositions.
IPSCIO Record ID: 248399
Plague Vaccine Dose shall mean a dose of recombinant protective antigen plague vaccine the manufacture, use, sale, keeping1 importing or exporting of which would, lo the absence of the license granted under this Agreement, constitute an infringement or actionable misuse of the Vaccine IP.
Patents are for Plague vacclnes and Vaccine Compositions.
The use beyond the United States is for inter alia the development of a prototype recombinant protective antigen plague vaccine and the production of trials doses thereof.
IPSCIO Record ID: 237265
Licensor grants a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import nucleic acid sequences encoding for such Additional Antigen in the Field, and to make, have made, use, sell, offer to sell and import Licensee Product(s) containing a nucleic acid sequence encoding for such Additional Antigen in the Field.
For the Licensors Applicator and/or Licensors Custom Components, Licensor grants an exclusive, sublicenseable license under the Licensors Patent Rights and Device Custom Know-How to use, sell, offer to sell and import Licensors Applicators and Licensors Custom Components solely for use with a Licensee Product in the Field.
For the Trademark License, Licensor grants a non-exclusive, sublicensable license in the Field in the Territory to use such trademarks and/or trade names Controlled by Licensor, to the extent that such trademarks and/or trade names relate to Licensors Technology, solely in connection with the use, sale, offer to sell and/or import of Licensee Product.
A single Indication shall include the primary disease and variants or sub-divisions or sub-classifications within such primary disease. For example, for purposes of the Agreement, breast cancer is a single Indication; treatment of and first line treatment of refractory metastatic breast cancer shall be treated as sub-classifications within the single Indication of breast cancer. Treatment and prophylaxis of the same disease (e.g. breast cancer) shall be treated as the same Indication.